Michael Burkes Brophy Sells 495 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 495 shares of the business’s stock in a transaction that occurred on Thursday, October 23rd. The shares were sold at an average price of $187.16, for a total value of $92,644.20. Following the completion of the sale, the chief financial officer owned 69,944 shares of the company’s stock, valued at $13,090,719.04. The trade was a 0.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, October 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The shares were sold at an average price of $196.77, for a total value of $148,561.35.
• On Wednesday, October 22nd, Michael Burkes Brophy sold 920 shares of Natera stock. The shares were sold at an average price of $186.68, for a total value of $171,745.60.
• On Tuesday, October 21st, Michael Burkes Brophy sold 602 shares of Natera stock. The shares were sold at an average price of $187.95, for a total value of $113,145.90.
• On Tuesday, September 30th, Michael Burkes Brophy sold 2,491 shares of Natera stock. The shares were sold at an average price of $162.05, for a total value of $403,666.55.
• On Tuesday, July 29th, Michael Burkes Brophy sold 3,045 shares of Natera stock. The shares were sold at an average price of $137.40, for a total value of $418,383.00.
• On Monday, July 28th, Michael Burkes Brophy sold 2,019 shares of Natera stock. The shares were sold at an average price of $139.81, for a total value of $282,276.39.

Natera Stock Down 1.3%

Shares of Natera stock opened at $192.51 on Friday. The company has a market cap of $26.42 billion, a PE ratio of -100.79 and a beta of 1.74. The business has a 50 day moving average of $171.29 and a 200 day moving average of $160.37. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $198.99.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. Natera’s revenue was up 32.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Investors Weigh In On Natera

Institutional investors have recently modified their holdings of the stock. Bank of Jackson Hole Trust purchased a new stake in shares of Natera in the first quarter worth $29,000. Hilltop National Bank purchased a new stake in shares of Natera in the second quarter worth $33,000. Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Natera in the second quarter worth $36,000. Sound Income Strategies LLC grew its stake in shares of Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after acquiring an additional 110 shares during the last quarter. Finally, TCTC Holdings LLC grew its stake in shares of Natera by 114.8% in the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after acquiring an additional 124 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on NTRA shares. Piper Sandler restated an “overweight” rating and set a $220.00 target price (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. Barclays restated an “overweight” rating and set a $210.00 target price (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Saturday. Royal Bank Of Canada set a $268.00 price target on Natera and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Finally, Wells Fargo & Company started coverage on Natera in a research note on Monday, September 22nd. They issued an “equal weight” rating and a $175.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $197.59.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.